Researchers have uncovered a stealth survival strategy that melanoma cells use to evade targeted therapy, offering a ...

Researchers have uncovered a promising therapeutic target for adenoid cystic carcinoma (ACC), a rare cancer of the salivary ...

Heavy alcohol consumption is a leading cause of gastrointestinal diseases, with binge drinking linked to increased intestinal ...

Targeted inhibition of a "signal jammer" protein may improve how tumors respond to immunotherapy. Published today in Nature , a new study demonstrates how some cancer cells use the protein ...

ZyVersa Therapeutics (ZVSA) highlights newly published animal model data demonstrating that inflammasome inhibition attenuates ...

Researchers at Kumamoto University have successfully executed a practical trial of a new genome-editing technique that allows ...

The center–surround receptive-field organization in retinal ganglion cells is widely believed to result mainly from lateral inhibition at the first synaptic level (in the outer retina).

(NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an ...

Previous studies revealed a positive correlation between O-GlcNAcylation and tumor growth via the stabilization of target proteins, with O-GlcNAcylation transferase (OGT) being the only enzyme capable ...

Current guidelines lack consensus and rely on lower-quality evidence, according to the author of new research.

MGNX earnings call for the period ending December 31, 2024. MacroGenics ( MGNX -2.75%) Q4 2024 Earnings Call Mar 20, 2025, ...

Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25Progression of preclinical next-generation ...